Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early February VC Tally: 6 Biotech Firms Raise $153.5m

This article was originally published in Scrip

Executive Summary

Will biotechnology firms in 2016 keep up the momentum that resulted in a record-breaking $7.4bn in US venture capital raised by the industry last year? It's possible if early-stage funding keeps up January's brisk pace, but it's too soon to tell if February will be a boom or a bust.

You may also be interested in...



Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Amplyx Raises $67m For Antifungals Against Life-Threatening Pathogens

Investors were impressed by the company's broad-spectrum, IV and oral antifungal drug in a space where few treatment options exist; Phase II trials will start later this year.

Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round

Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.

Related Content

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel